Garuda Therapeutics
Cambridge · Biotechnology, Health Care, Science And Engineering · 55 employees
Garuda Therapeutics seeks to eliminate the need for stem cell donors for blood stem cell transplants. Garuda’s proprietary off-the-shelf hematopoietic stem cell (HSC) therapies enable self-renewing, HLA compatible and transgene-free HSCs, available immediately for patients. An immediately available, off-the-shelf option for patients could provide much needed strategies in a multitude of blood diso
Funding history
- Series series a — $50.0M — Mar 2025
- Funding Round — $47.7M — Oct 2024
- Funding Round — $62.1M — Feb 2023
- Funding Round — $48.1M — Sep 2021
- Series series a — $72.0M — Sep 2021
Recent signals
- Mar 06, 2025: Garuda Therapeutics Appoints Avanish Vellanki as Chief Executive Officer
- Mar 05, 2025: Raised $50.0M in Series series a
- Oct 31, 2024: Raised $47.7M
- Jul 12, 2023: Garuda Therapeutics Appoints Giorgia Scapin, Ph.D., as Chief Scientific Officer | citybiz
- Feb 03, 2023: Raised $62.1M
- Sep 24, 2021: Raised $48.1M
- Sep 23, 2021: Raised $72.0M in Series series a
See plans & pricing → Track Garuda Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.